Vepafestinib is under clinical development by Helsinn Healthcare and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vepafestinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vepafestinib overview
Vepafestinib is under development for the treatment solid tumors with RET mutations and non-small cell lung cancer. It is administered through oral route. The drug candidate acts by targeting proto-oncogene tyrosine-protein kinase receptor RET.
See Also:
It was under development for the treatment of papillary and medullary thyroid cancer.
Helsinn Healthcare overview
Helsinn Healthcare, a subsidiary of Helsinn Holding SA, is a cancer care company that offers oncology products and therapies. The company includes research and development, drug discovery and manufacturing of formulations of drug products in therapeutic areas of pain and inflammation, cancer supportive care and gastroenterology. Its products comprise Aloxi, Gelclair, Akynzeo, Nimesulide, Klean-Prep and laxaclear. The company also offers integrated early and late-stage licensing programs for its own drug discovery and development programs. It operates research and development facilities in Dublin, Ireland, Biasca, Switzerland and supplies products across the US, Monaco, Japan and China. Helsinn Healthcare is headquartered in Lugano, Switzerland.
For a complete picture of Vepafestinib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
